The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI:10.1002/pbc.31475

Charles T Quinn, Russell E Ware

引用次数: 0

Abstract

Voxelotor (OXBRYTA) was abruptly withdrawn from the global market in September 2024. Clinicians and patients were not prepared for this, and the sudden discontinuation has caused much consternation, uncertainty, and loss of trust.

查看原文本刊更多论文

伏西洛效应：镰状细胞病新药亲和力降低？

Voxelotor （OXBRYTA）于2024年9月突然退出全球市场。临床医生和患者没有为此做好准备，突然停止治疗造成了很大的恐慌、不确定性和信任的丧失。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.